Nūhou
Ke Koʻikoʻi Lapaʻau o nā Pūhui Protein Oligoclonal Ma hope o ka BCMA CAR-T Therapy i nā maʻi Myeloma Multiple
Ua loiloi kahi noiʻi retrospective i ka hanana a me nā hopena o nā hui protein oligoclonal (APB) i nā maʻi myeloma multiple (MM) relapsed/refractory i mālama ʻia me ka lāʻau LCAR-B38M CAR-T, e hōʻike ana i kā lākou pilina me nā hopena i hoʻomaikaʻi ʻia.
Ka Moʻolelo o ka Mea Maʻi: Mai ka ʻIke AML-M2 a i kahi Freshman o ke Kulanui - He Huakaʻi ʻElima Makahiki i ka Hoʻōla ʻana
ʻO ke kaua ʻelima makahiki o kahi maʻi leukemia ʻōpio e kūʻē iā AML-M2, i hoʻopau ʻia i kahi hoʻoili cell kumu haploidentical holomua ma ka Halemai ʻo Lu Daopei, e hoʻomākaukau ana i ke ala no kona ola hou ma ke ʻano he haumāna kulanui.
Hōʻike ka Haʻawina Multi-Center i ka Prognosis Maikaʻi no nā Maʻi Hematoma Malignancy e Hana ʻia ana e ka MMUD Allogeneic Stem Cell Transplant me ATG
Ua hōʻike ʻia kahi noiʻi nui ma waena o nā kikowaena ma Kina i nā hopena maikaʻi no nā poʻe maʻi me nā maʻi hematologic e hana nei i nā hoʻoili cell stem mismatched related donor (MMUD) me ATG no ka pale ʻana i ka GVHD.
Ka Moʻolelo o ka Mea Maʻi: B-ALL Kiʻekiʻe-Pilikia, Hoʻoili ʻana o ka Iwi ʻŌpū i 9 Mahina, ʻElua Makahiki Mahope Mai—He Hoʻomaka Olakino no kahi Koa ʻŌpio
Ua hana ʻia kahi hoʻoili iwi iwi kūleʻa i kahi keiki 9 mahina, i ʻike ʻia he Acute B Lymphoblastic Leukemia (B-ALL). ʻElua mau makahiki ma hope mai, ua ulu maikaʻi ke keiki a ua mākaukau no ke kula kamaliʻi.
Hoʻolalelale i ka hoʻomākaukau ʻana o ke kelepona CAR-T e hoʻomaikaʻi i nā hopena o ka mea maʻi
He loiloi hou i loko o ʻO ka Lancet Haematology hōʻike i nā holomua hou i ka lāʻau lapaʻau CAR-T cell, e kālele ana i ka hoʻonui ʻana i ka wikiwiki o ka hana ʻana, ka hoʻomaikaʻi ʻana i ka pono o ka lāʻau lapaʻau, a me ka hoʻonui ʻana i ke komo ʻana no nā poʻe maʻi me ke koko a me nā puʻupuʻu paʻa.
Hōʻike ka Brexu-cel CAR-T Therapy i nā hopena maikaʻi i nā poʻe maʻi R/R B-ALL makua
He noiʻi hou i loko o ka Ka Nūpepa o ka Oncology Lapaʻau hōʻike i nā hopena maikaʻi no ka lāʻau CD19 CAR-T brexucabtagene autoleucel (brexu-cel) i ka mālama ʻana i ka relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), e hāʻawi ana i ka manaʻolana no nā helu kala kiʻekiʻe a me ka hoʻomaikaʻi ʻana i ke ola ʻana ma nā wahi honua maoli.
Ke Hoʻomaopopo nei i ka Thalassemia: He Alakaʻi Piha i nā ʻAno Alpha a me Beta
ʻOi aku ma mua o hoʻokahi maʻi ka Thalassemia. Ke nānā nei kēia alakaʻi i ka alpha a me ka beta thalassemia, ko lākou mau kumu, nā hōʻailona, a me nā koho lapaʻau hou loa i loaʻa ma BIOOCUS International Medical Center.
Mai ka hāʻule mua ʻana o ka Graft a hiki i ka ho'ōla piha ʻana: Ka huakaʻi a ka mea maʻi me ka Advanced Transplant Protocol a Lu Daopei
Ma hope o ka loaʻa ʻana o kahi maʻi leukemia B-lymphoblastic koʻikoʻi me ka pilikia nui a me ka hāʻule mua ʻana o ka hoʻoili ʻana, ua like ke ala o ka mea maʻi i ka hoʻōla ʻana me he mea lā he mea pohihihi. Eia nō naʻe, ma o ka ʻike loea o ka hui lapaʻau o Lu Daopei a me ka lua o ka hoʻoili ʻana mai kahi mea hāʻawi ʻaʻole pili, ua hoʻi mai ka manaʻolana a me ke olakino.
Ke Ola Nei i nā Pilikia: He Huakaʻi 14 Makahiki o ke Kūpaʻa i ke Kaua e Kūʻē i ka Stage IV Melanoma
ʻO Jennifer Ficko, i ʻike ʻia me ka melanoma pae IV i ka makahiki 48, ua kūʻē ʻo ia i nā manaʻolana āpau. Ma o nā lāʻau lapaʻau hou e like me ka TIL therapy a me ke kākoʻo paʻa ʻole o kona ʻohana, ua noho ʻo ia me ka ʻole o ka maʻi kanesa no nā makahiki ʻehiku a ʻoi, e hoʻolauleʻa ana i kahi ola kupaianaha he 14 mau makahiki.
Ke Lanakila ʻana i ka Leukemia: ʻO ka Huakaʻi o ke Kūpaʻa a me ka Manaʻolana o kahi Kaikamahine ʻŌpio ma ka Halemai ʻo Lu Daopei
I ka makahiki 2016, ua ʻike ʻia kekahi kaikamahine he 11 makahiki, ʻo Wenwen (inoa kapakapa), me ka maʻi leukemia lymphoblastic T-cell acute. I ke alo ʻana i nā pilikia e hoʻoweliweli ana i ke ola, ua huli ʻo ia a me kona ʻohana i ka Halemai ʻo Lu Daopei no ka mālama ʻana. I kēia lā, ma hope o kahi hoʻoili holomua a me nā makahiki o ka hoʻōla ʻana, ke ulu nei ʻo ia a ke hoʻomākaukau nei no kāna mau hoʻokolohua komo kulanui.
Hōʻike ka NK Cell Therapy i hui pū ʻia me ka DC Vaccine i ka hoʻomaikaʻi nui ʻana i ka maʻi kanesa o ke akepaʻa hope loa
Ua puka mai kahi holomua i ka mālama ʻana i ka maʻi kanesa akepaʻa holomua ma o ka hui pū ʻana o ka lāʻau lapaʻau NK cell, ka lāʻau pale DC, a me Nivolumab. Ua hōʻike kēia immunotherapy i hui pū ʻia i ka holomua kupaianaha, e alakaʻi ana i ka hōʻemi nui ʻana o ka puʻupuʻu a me ka hoʻomaikaʻi ʻana i ka hana o ke akepaʻa i loko o ʻeono pule wale nō no kahi mea maʻi me ka hepatocellular carcinoma hope loa.
Hōʻike ʻo Kauka Lu Peihua i ka holomua ma ka CAR-T Therapy ma ka 29th APBMT Annual Meeting
Ma ka Hālāwai Makahiki 29 o ka Hoʻoili Koko a me ka ʻAoʻao o ka ʻĀina ʻĀsia-Pasifika (APBMT), ua hāʻawi ʻo Kauka Lu Peihua i kahi haʻiʻōlelo koʻikoʻi e pili ana i ka holomua o ka lāʻau lapaʻau CAR-T ma Kina. Ua loaʻa i ka ʻikepili maoli o kāna hui mai ka hana lapaʻau ka mahalo honua, e hōʻike ana i kā lākou hāʻawi ʻana i ka mālama ʻana i nā maʻi koko.